OneCell Diagnostics is now 1Cell.Ai

CTC-Based Liquid Biopsy for Early Detection of Relapse and MRD Monitoring

OncoDiscover® is a patented, innovative test designed to detect and monitor Circulating Tumor Cells (CTCs) in the bloodstream.
Built on a proprietary multicomponent nanotechnology platform (OncoViu® Kit), it enables real-time tracking of minimal residual disease (MRD) and potential metastatic spread in patients post-treatment—offering earlier relapse detection than traditional imaging.

Detect Cancer Progression Before It Becomes Visible

CTCs are cancer cells that escape from the primary tumor and circulate in the bloodstream. They serve as seeds for metastasis and are key markers for monitoring disease status.

OncoDiscover® provides oncologists with a sensitive, non-invasive tool to detect minimal residual disease (MRD) and track recurrence earlier than conventional methods like CT or MRI scans.

Detects and monitors disease relapse through CTC analysis

Enables early identification of minimal residual disease (MRD)

Non-invasive blood test requiring only a 5 mL sample

Patented multicomponent CTC capture platform (PCT/IB2016/050779)

Rapid turnaround time (TAT = 7 Days) from sample collection to report

ISO 13485:2016 certified laboratory analysis

How It Works

1) Advanced CTC Capture

The OncoDiscover® platform uses a proprietary nanoparticle-based capture system (OncoViu® Kit) combining iron oxide, glutathione, dendrimers (PAMAM), graphene, and targeting antibodies to selectively isolate CTCs from blood samples.

2 ) CTC Characterization

Captured CTCs are characterized using markers such as CD45, CK18, and DAPI, confirming their identity as tumor-derived cells.

3) MRD Monitoring

Detection of CTCs enables early monitoring of minimal residual disease, often months before conventional imaging can reveal clinical signs of recurrence.

Applications

For Clinicians & Oncologists

  • Monitor MRD in post-treatment cancer patients

  • Enable earlier therapeutic interventions upon detection of disease relapse

  • Track metastatic progression in real time

For Cancer Patients

  • Gain non-invasive post-treatment surveillance

  • Access earlier detection of relapse, potentially improving outcomes

Why Choose OncoDiscover

  • Patented technology validated under international standards

  • Licensed by DCG(I) (License No. MFG/IVD/2019/000031)

  • Recognized with “Innovator of the Year 2019” award by the Department of Biotechnology, Government of India

  • Backed by ISO 13485:2016 certification

  • Designed to fit real-world clinical needs with affordable logistics and fast reporting

Logistics and TAT

  
Patient CounselingPatient referred by oncologist for OncoDiscover® CTC Test
Sample Collection5 mL blood collected into vacutainer tube
Sample TransportSent under controlled conditions to 1Cell.Ai lab in Pune
Sample AnalysisPerformed using the OncoViu® Liquid Biopsy Kit
Report DeliveryEmailed to the referring oncologist within 7 days

CTCs and Minimal Residual Disease (MRD)

  • CTCs: Shed by the primary tumor into the bloodstream; indicators of potential metastasis.
  • CTC Clusters: Groups of two or more tumor cells; associated with higher metastatic potential compared to individual CTCs.
  • MRD Detection: Persistence of CTCs after treatment indicates the presence of residual disease not detectable by imaging.
  • Clinical Impact: Monitoring CTCs can detect recurrence months earlier than radiological scans, enabling proactive treatment decisions.
1Cell.Ai
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.